Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale
Tonix Pharmaceuticals Holding Corp. (TNXP)
Last tonix pharmaceuticals holding corp. earnings: 3/24 05:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
tonixpharma.com
Company Research
Source: GlobeNewswire
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that it will present at Noble Capital Markets’ Fourteenth Annual Investor Conference being held January 29-30, 2018 in Fort Lauderdale. Tonix is in Phase 3 development of Tonmya®*(cyclobenzaprine HCI sublingual tablets), or TNX-102 SL, a U.S. Food and Drug Administration-designated Breakthrough Therapy for the treatment of posttraumatic stress disorder (PTSD). Seth Lederman, M.D., president and chief executive officer of Tonix, will provide an update of the Tonix pipeline of development programs. Details of the presentation are as follows: Event: NobleCon14 – Noble Capital Markets’ Fourteenth Annual Investor ConferenceDate: Monday, January 29, 2018Time: 4 p.m. ESTLocation: Studio 2, W Fort Lauderdale Hotel, Fort Lauderdale, FL A high-definition, video webcast of the presentation will be available approximately 24 hours following the live presentation. The webcast
Show less
Read more
Impact Snapshot
Event Time:
TNXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNXP alerts
High impacting Tonix Pharmaceuticals Holding Corp. news events
Weekly update
A roundup of the hottest topics
TNXP
News
- Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct OfferingGlobeNewswire
- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome [Yahoo! Finance]Yahoo! Finance
- Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi SyndromeGlobeNewswire
TNXP
Sec Filings
- 3/25/24 - Form 8-K
- 3/21/24 - Form 8-K
- 3/20/24 - Form 8-K
- TNXP's page on the SEC website